# US 2023/0331656 A1 · Nanomaterials comprising acetals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0331656 A1
- Document ID: US20230331656A1
- Status: Published application
- Kind: A1
- Application number: 18/211,822
- Filed: 2023-06-20
- Published: 2023-10-19
- Earliest claimed: 2020-12-21
- Assignees: Beam Therapeutics Inc.
- Applicants: Beam Therapeutics Inc.
- Inventors: Gregory Lawrence Hamilton; Neeraj Narendra Patwardhan; Cory Dane Sago; Mina Fawzy Shehata; Milloni Balwantkumar Chhabra
- Web page: https://patentgrep.com/patent/US20230331656A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- C07C 229/12: to carbon atoms of acyclic carbon skeletons
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 31/75: of ethene
- A61K 39/385: Haptens or antigens, bound to carriers
- C07C 217/40: having at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the same carbon atom of the carbon skeleton, e.g. amino-ketals, ortho esters
- C07C 219/04: the carbon skeleton being acyclic and saturated
- C07C 219/06: having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C 229/22: the carbon skeleton being further substituted by oxygen atoms
- C07D 207/04: having no double bonds between ring members or between ring members and non-ring members
- C07C 2603/74: Adamantanes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

## Claims

### Claim 1

A compound of Formula I′:
or its N-oxide, or a pharmaceutically acceptable salt thereof, wherein
L1 is absent, C1-6 alkylenyl, or C2-6 heteroalkylenyl;
each L2 is independently optionally substituted C2-15 alkylenyl or optionally substituted C3-15 heteroalkylenyl;
L3 is absent, optionally substituted C1-10 alkylenyl, or optionally substituted C2-10 heteroalkylenyl;
X is absent, —OC(O)—, —C(O)O—, or —OC(O)O—;
each R′ is independently an optionally substituted group selected from C4-12 aliphatic, 3- to 12-membered cycloaliphatic, 7- to 12-membered bridged bicyclic comprising 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 1-adamantyl, 2-adamantyl, sterolyl, and phenyl;
R is hydrogen,
or an optionally substituted group selected from C6-20 aliphatic, 3- to 12-membered cycloaliphatic, 7- to 12-membered bridged bicyclic comprising 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 1-adamantyl, 2-adamantyl, sterolyl, and phenyl;
R1 is hydrogen, optionally substituted phenyl, optionally substituted 3- to 7-membered cycloaliphatic, optionally substituted 3- to 7-membered heterocyclyl comprising 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 5- to 6-membered monocyclic heteroaryl comprising 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 8- to 10-membered bicyclic heteroaryl comprising 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, —OR2, —C(O)OR2, —C(O)SR2, —OC(O)R2, —OC(O)OR2, —CN, —N(R2)2, —C(O)N(R2)2, —S(O)2N(R2)2, —NR2C(O)R2, —OC(O)N(R2)2, —N(R2)C(O)OR2, —NR2S(O)2R2, —NR2C(O)N(R2)2, —NR2C(S)N(R2)2, —NR2C(NR2)N(R2)2, —NR2C(CHR2)N(R2)2, —N(OR2)C(O)R2, —N(OR2)S(O)2R2, —N(OR2)C(O)OR2, —N(OR2)C(O)N(R2)2, —N(OR2)C(S)N(R2)2, —N(OR2)C(NR2)N(R2)2, —N(OR2)C(CHR2)N(R2)2, —C(NR2)N(R2)2, —C(NR2)R2, —C(O)N(R2)OR2, —C(R2)N(R2)2C(O)OR2, —CR2(R3)2, —OP(O)(OR2)2, or —P(O)(OR2)2; or
R1 is
or a ring selected from 3- to 7-membered cycloaliphatic and 3- to 7-membered heterocyclyl comprising 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the cycloaliphatic or heterocyclyl ring is optionally substituted with 1-4 R2 or R3 groups;
each R2 is independently hydrogen, oxo, —CN, —NO2, —OR4, —S(O)2R4, —S(O)2N(R4)2, —(CH2)n—R4, or an optionally substituted group selected from C1-6 aliphatic, phenyl, 3- to 7-membered cycloaliphatic, 5- to 6-membered monocyclic heteroaryl comprising 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 3- to 7-membered heterocyclyl comprising 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or
two occurrences of R2, taken together with the atom(s) to which they are attached, form optionally substituted 4- to 7-membered heterocyclyl comprising 0-1 additional heteroatom selected from nitrogen, oxygen, and sulfur;
each R3 is independently —(CH2)n—R4; or
two occurrences of R3, taken together with the atom(s) to which they are attached, form optionally substituted 5- to 6-membered heterocyclyl comprising 0-1 additional heteroatom selected from nitrogen, oxygen, and sulfur;
each R4 is independently hydrogen, —OR5, —N(R5)2, —OC(O)R5, —OC(O)OR5, —CN, —C(O)N(R5)2, —NR5C(O)R5, —OC(O)N(R5)2, —N(R5)C(O)OR5, —NR5S(O)2R5, —NR5C(O)N(R5)2, —NR5C(S)N(R5)2, —NR5C(NR5)N(R5)2, or
each R5 is independently hydrogen or optionally substituted C1-6 aliphatic; or
two occurrences of R5, taken together with the atom(s) to which they are attached, form optionally substituted 4- to 7-membered heterocyclyl comprising 0-1 additional heteroatom selected from nitrogen, oxygen, and sulfur;
each R6 is independently C4-12 aliphatic; and
each n is independently 0 to 4.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula I-a:
or its N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula I-b:
or its N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula I-c:
or its N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula I-e:
or its N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein the compound is of Formula I-e-i:
or its N-oxide, or a pharmaceutically acceptable salt thereof.

### Claim at position 7

7-8. (canceled)

### Claim 9 (depends on 1)

The compound according to claim 1, wherein L1 is C1-5 alkylenyl.

### Claim at position 9

10-11. (canceled)

### Claim 12 (depends on 1, 2, 3, 4)

The compound according to claim 1-4, wherein each L2 is independently C5-10 alkylenyl.

### Claim at position 11

13-14. (canceled)

### Claim 15 (depends on 1)

The compound according to claim 1, wherein L3 is C2-4 alkylenyl.

### Claim 16 (depends on 1)

The compound according to claim 1, wherein each R′ is independently optionally substituted C4-12 alkyl, optionally substituted C4-12 alkenyl, or optionally substituted C4-12 alkynyl, wherein when each R′ is independently optionally substituted C4-12 alkyl, X is —OC(O)O—.

### Claim 17 (depends on 16)

The compound according to claim 16, wherein each R′ is independently C4-12 alkenyl, C4-12 alkynyl, or C4-12haloaliphatic.

### Claim 18 (depends on 16)

The compound according to claim 16, wherein each R′ is independently selected from the group consisting of

### Claim 19 (depends on 1)

The compound according to claim 1, wherein each
is independently selected from the group consisting of

### Claim 20 (depends on 1)

The compound according to claim 1, wherein R is hydrogen or an optionally substituted group selected from C6-20 aliphatic, 3- to 7-membered cycloaliphatic, 1-adamantyl, 2-adamantyl, sterolyl, and phenyl.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The compound according to claim 1, wherein -L3-R is selected from the group consisting of

### Claim 23 (depends on 1)

The compound according to claim 1, wherein R1 is optionally substituted 3- to 7-membered heterocyclyl comprising 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, —OR2, or —CR2(R3)2.

### Claim 24 (depends on 1)

The compound according to claim 1, wherein R1 is —OR2, —CR2(R3)2, or 3- to 7-membered heterocyclyl comprising 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclyl ring is optionally substituted with 1-4 R2 or R3 groups.

### Claim 25 (depends on 24)

The compound according to claim 24, wherein R1 is —OR2, —CR2(R3)2,

### Claim 26 (depends on 1)

The compound according to claim 1, wherein each R2 is independently hydrogen, oxo, or —(CH2)n—R4.

### Claim 27 (depends on 1)

The compound according to claim 1, wherein each R4 is independently —OR5.

### Claim 28 (depends on 1)

The compound according to claim 1, wherein each R5 is hydrogen.

### Claim 29 (depends on 1)

The compound according to claim 1, wherein R1 is selected from the group consisting of

### Claim 30

A compound selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 1)

A lipid nanoparticle (LNP) preparation comprising an ionizable lipid, wherein the ionizable lipid is a compound according to claim 1.

### Claim 32 (depends on 30)

A lipid nanoparticle (LNP) preparation comprising
an ionizable lipid, wherein the ionizable lipid is a compound according to claim 30.

### Claim at position 30

33-39. (canceled)

### Claim 40 (depends on 31)

A pharmaceutical composition comprising a LNP preparation of claim 31 and a pharmaceutically acceptable excipient.

### Claim 41 (depends on 31)

A method for administering a therapeutic and/or prophylactic agent to a subject in need thereof, the method comprising administering the LNP preparation of claim 31 to the subject.

### Claim 42 (depends on 31)

A method for treating a disease or a disorder in a subject in need thereof, the method comprising administering the LNP preparation of claim 31 to the subject, wherein the therapeutic and/or prophylactic agent is effective to treat the disease.

### Claim 43

(canceled)

### Claim 44 (depends on 31)

A method of delivering a therapeutic and/or prophylactic agent to a mammalian cell derived from a subject, the method comprising contacting the cell of the subject having been administered the LNP preparation of claim 31.

### Claim at position 36

45-50. (canceled)
